{"url_path":"/sec/nvct/8-k/2026-06-23/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-23","source_url":"https://www.sec.gov/Archives/edgar/data/1875558/0001104659-26-076624-index.html","accession_number":"0001104659-26-076624","cik":"0001875558","ticker":"NVCT","issuer_name":"Nuvectis Pharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1875558/0001104659-26-076624-index.html","primary_entity_key":"0001875558","primary_entity_name":"Nuvectis Pharma, Inc."},"word_count":58,"has_tables":true,"body_markdown":"** **\n\n**Item 8.01. **\n**Other Events.**\n\n \n\nOn June 22, 2026, the Company\nissued a press release to announce its entry into the License Agreement. The full text of the press release is filed as Exhibit\n99.1 to this Current Report on Form 8-K and is incorporated herein by reference (except for the third and fourth paragraphs of the press\nrelease)."}